TVARDI THERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
TVARDI THERAPEUTICS, INC. (TVRD) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$2.70 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-15.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-15
- TVARDI THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$2.40M, a 136.06% decline year-over-year.
- TVARDI THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $2.38M, a 26.32% increase year-over-year.
- TVARDI THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $4.11M.
- TVARDI THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$6.79M.
- TVARDI THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$2.70M.
- TVARDI THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$3.01M.
- TVARDI THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$37.56M, a 193.19% decline from fiscal 2014.
- TVARDI THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $40.31M, a 258.59% increase from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$28.00K derived: sum of 2 quarters · filed 2018-03-15 | $4.08M derived: sum of 3 quarters · filed 2018-03-15 | -$2.70M 10-K · filed 2018-03-15 |
| 2017-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $6.49M derived: sum of 2 quarters · filed 2017-11-02 | -$300.00K 10-Q · filed 2017-11-02 | $6.37M derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-06-30 | $4.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$2.68M 10-Q · filed 2017-08-03 | $3.99M derived: sum of 3 quarters · filed 2018-03-15 | $5.87M derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-03-31 | -$6.79M 10-Q · filed 2017-05-04 | -$120.00K derived: sum of 2 quarters · filed 2018-03-15 | $1.76M derived: sum of 3 quarters · filed 2018-03-15 | -$2.62M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-12-31 | $6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $8.55M derived: sum of 2 quarters · filed 2018-03-15 | $4.17M derived: sum of 3 quarters · filed 2018-03-15 | -$3.01M 10-K · filed 2018-03-15 |
| 2016-09-30 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$2.50M derived: sum of 2 quarters · filed 2017-11-02 | -$9.68M 10-Q · filed 2017-11-02 | -$105.69M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | -$4.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$11.56M 10-Q · filed 2017-08-03 | -$107.57M derived: sum of 3 quarters · filed 2018-03-15 | -$39.65M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-03-31 | -$7.18M 10-Q · filed 2017-05-04 | -$103.19M derived: sum of 2 quarters · filed 2018-03-15 | -$35.27M derived: sum of 3 quarters · filed 2018-03-15 | -$39.50M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-12-31 | -$96.02M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$28.09M derived: sum of 2 quarters · filed 2018-03-15 | -$32.32M derived: sum of 3 quarters · filed 2018-03-15 | -$37.56M 10-K · filed 2018-03-15 |
| 2015-09-30 | $67.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $63.69M derived: sum of 2 quarters · filed 2016-11-04 | $58.45M 10-Q · filed 2016-11-04 | $52.72M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | -$4.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$9.47M 10-Q · filed 2016-08-04 | -$15.20M derived: sum of 3 quarters · filed 2017-03-10 | -$19.62M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | -$5.24M 10-Q · filed 2016-05-05 | -$10.97M derived: sum of 2 quarters · filed 2017-03-10 | -$15.39M derived: sum of 3 quarters · filed 2017-03-10 | -$19.62M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | -$5.73M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$10.15M derived: sum of 2 quarters · filed 2017-03-10 | -$14.38M derived: sum of 3 quarters · filed 2017-03-10 | $40.31M 10-K · filed 2017-03-10 |
| 2014-09-30 | -$4.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$8.64M derived: sum of 2 quarters · filed 2015-11-09 | $46.04M 10-Q · filed 2015-11-09 | $40.66M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | -$4.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $50.45M 10-Q · filed 2015-08-10 | $45.08M derived: sum of 3 quarters · filed 2016-03-11 | $41.63M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $54.68M 10-Q · filed 2015-05-12 | $49.30M derived: sum of 2 quarters · filed 2016-03-11 | $45.86M derived: sum of 3 quarters · filed 2016-03-11 | $66.35M derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | -$5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | -$8.82M derived: sum of 2 quarters · filed 2016-03-11 | $11.67M derived: sum of 3 quarters · filed 2016-03-11 | $11.24M 10-K · filed 2016-03-11 |
| 2013-09-30 | -$3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $17.04M derived: sum of 2 quarters · filed 2014-11-10 | $16.62M 10-Q · filed 2014-11-10 | |
| 2013-06-30 | $20.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $20.06M 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | -$427.00K 10-Q · filed 2014-05-12 | |||
| 2012-12-31 | -$2.98M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |